Gene editing investors may soon have one more stock to choose from. A gene-editing company called Metagenomi $MGX uses AI to discover novel CRISPR gene editing methods from nature and they're planning to have an IPO. We start by looking at all the current players according to the IPO S-1 filing, then describe what the ideal gene editing business model looks like. Then, we describe how MGX plans to compete against CRISPR CAS9 competitors like CRISPR Therapeutics and Intellia Therapeutics. Basically, they have better technology - a platform that uses AI to discover gene editing tools - and they believe the intellectual property constraints won't apply to them. Would be buy Metagenomi stock? How about we wait for the IPO to happen first ;) We list out some milestones for gene editing investors to watch and look at how we expect the company to progress. Seems like there's never been a better time to invest in gene editing, but it's anybody's game with all the external risks. And there can be more than one winner.


Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/8k83pekwtcU.

Ver todos los episodios